What Happens When You Stop a GLP-1 With PMOS

Stopping a GLP-1 with PMOS is the part nobody plans for. The starting conversation covers dose, side effects and how much you might lose. The stopping conversation usually happens after the fact, when the weight is already returning and it feels personal.

It is not personal. Three large randomised withdrawal trials have measured exactly what happens when these drugs stop, and the pattern is consistent enough to plan around. This page gives you the real numbers, what happens to your PMOS symptoms specifically, and what actually helps.

PMOS is Polyendocrine Metabolic Ovarian Syndrome, the clinical name adopted for PCOS in May 2026. GLP-1 medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

What happens when you stop a GLP-1?

You regain most of the lost weight over about a year. The best evidence is the STEP 1 trial extension, which followed 327 participants for a full year after semaglutide was withdrawn.

Mean weight loss was 17.3% at week 68 on semaglutide. By week 120, one year after stopping, participants had regained 11.6 percentage points, leaving a net loss of 5.6% from where they started.

The authors summarised it plainly: participants regained two-thirds of their prior weight loss. They also reported that the cardiometabolic improvements gained during treatment reverted toward baseline for most variables.

SURMOUNT-4 produced the starkest single statistic. Of those who continued tirzepatide, 89.5% kept at least 80% of their weight loss at week 88. Of those switched to placebo, 16.6% did.

Why does the weight come back?

Because the drug was doing the work, and stopping it removes the mechanism rather than resetting anything. GLP-1 medications suppress appetite and slow gastric emptying while they are in your system. Neither effect persists after the drug clears.

Body weight is also defended. After weight loss, appetite hormones shift toward hunger and resting energy expenditure falls. That response is normal physiology and it happens after any weight loss, drug or not.

What the withdrawal trials show is that the medication was holding that response in check, not eliminating it. When it stops, the underlying pressure is still there and it has been waiting.

What happens to PMOS symptoms when you stop?

This is the question the trials were not designed to answer, and honesty requires saying so. No withdrawal trial has tracked androgens, cycles or PMOS symptoms after stopping a GLP-1.

What can be reasoned from mechanism is this. The August 2026 tirzepatide trial in women with PMOS found the benefit ran through visceral fat, which fell by 34.13 cm2 against 4.67 cm2 with metformin alone. Visceral fat drives insulin resistance, insulin resistance drives ovarian androgen production, and androgens drive the symptoms.

If visceral fat returns, that chain most likely reassembles in the same order. The STEP 1 extension finding that cardiometabolic markers reverted toward baseline supports that direction, though it did not measure androgens.

Notably, that PMOS trial itself stopped tirzepatide at 16 weeks and switched everyone back to metformin, so even the PMOS-specific evidence contains no durability data.

Does the muscle come back?

Not automatically, and this is the most underrated risk in the whole stopping conversation. A 2026 meta-analysis of 36 randomised trials found that lean mass accounted for 28% of the total weight lost on GLP-1 medications, with an average lean body mass reduction of 1.51 kg.

Regained weight is preferentially fat unless you are training and eating enough protein to direct it otherwise. So the risk is not simply returning to your starting weight. It is returning to your starting weight with a worse body composition than you began with.

For PMOS this is the outcome to avoid, because skeletal muscle is the primary site of glucose disposal. Less muscle and the same weight means worse insulin sensitivity than before you started.

Is there a right way to come off?

No protocol has been trialled, so anyone presenting one as evidence-based is overselling it. What can be said is which decisions have evidence behind them and which are reasoned.

Evidence-based: continuing at a lower maintenance dose preserves more of the benefit than stopping entirely. In SURMOUNT-4 the continued group kept losing, and in STEP 4 the continued group kept losing. There is no trial of full dose against reduced dose in PMOS, but the direction of the maintenance evidence is consistent.

Reasoned, not proven: tapering slowly rather than stopping abruptly, building the eating and training habits before the taper rather than during it, and tracking waist circumference rather than only weight so you notice composition changes.

The single most useful thing is to decide in advance what you are stopping toward. Stopping without a plan is how the two-thirds figure becomes the whole thing.

What should you eat when coming off a GLP-1?

More than you think, and with protein protected first. Appetite returns before the habits do, which is the specific trap in this transition.

Protein first, at every meal. Your target is 1.2 to 1.6 g per kg of body weight. This directs regain toward lean tissue and blunts the appetite rebound, since protein is the most satiating macronutrient.

Volume and fibre. On the drug, small portions felt like enough. Off it, the same portions will not. Replacing that volume with vegetables and legumes keeps meals filling without reversing the calorie balance overnight.

Keep the structure. The most common failure is drifting back to unplanned eating once appetite returns. The plan is what carries you across the gap, not motivation.

Practical options from our recipe database:

• Broiled Salmon with Asparagus, 42 g protein in 453 calories. High protein density for a returning appetite.
• Spicy Chickpea Chole, 11 g protein in 244 calories. Fibre and volume for very little energy cost.
• Red Lentil Sweet Potato Curry, 19 g protein in 358 calories. Batch-cooks well, which matters when structure is the thing at risk.

Are you ready to come off?

Score one point for each statement that is true today, not the one you intend to start next month.

• I do resistance training at least twice a week, consistently.
• I know my protein target in grams and hit it most days.
• I have a repeatable set of meals I actually like.
• I track waist circumference, not only body weight.
• I have discussed a maintenance dose with my prescriber.
• I know what specifically triggered my previous regains.

5 to 6 points. You have the scaffolding. Discuss a slow taper or a maintenance dose with your prescriber.

3 to 4 points. Close the gaps before you taper. The missing habit is the one that will decide the outcome.

0 to 2 points. Stopping now reproduces the trial conditions almost exactly, which means the two-thirds figure is your likely result. Build the habits while the drug is still making that easy.

Myths about stopping a GLP-1

Myth: Regaining weight after stopping means you failed.
Reality: In SURMOUNT-4, 83.4% of people switched to placebo failed to keep 80% of their loss. That is not a character distribution. That is what the drug stopping looks like. Share this

Myth: You take a GLP-1 until you reach your goal, then stop.
Reality: Every withdrawal trial found substantial regain. The STEP 1 authors concluded that ongoing treatment is required to maintain improvements in weight and health. Share this

Myth: The metabolic benefits stay even if the weight returns.
Reality: The STEP 1 extension found cardiometabolic improvements reverted toward baseline for most variables one year after withdrawal. Share this

Myth: You will just go back to your old weight.
Reality: Regain is preferentially fat, while 28% of what you lost was lean mass. Same weight, less muscle, worse insulin sensitivity than you started with. Share this

Myth: Tapering slowly prevents regain.
Reality: No trial has tested tapering schedules. It is a reasonable idea with no evidence behind it. What does have evidence is continuing at a maintenance dose. Share this

Frequently asked questions

How much weight will I regain after stopping Ozempic?
About two-thirds of what you lost, over roughly a year. The STEP 1 trial extension followed 327 participants for a full year after semaglutide withdrawal. Mean weight loss was 17.3% at week 68. By week 120 participants had regained 11.6 percentage points, leaving a net 5.6% below their starting weight. The authors described this as regaining two-thirds of prior weight loss. STEP 4 found a consistent pattern over a shorter window: participants switched to placebo gained 6.9% over 48 weeks while those continuing lost a further 7.9%. Individual results vary, but no trial has found a group that kept it all.

Is regain worse with Mounjaro than Ozempic?
The numbers look larger with tirzepatide, but they are not directly comparable. SURMOUNT-4 found people switched from tirzepatide to placebo gained 14.0% of body weight over 52 weeks, against 6.9% over 48 weeks in STEP 4 with semaglutide. The trials differed in design and duration, and tirzepatide participants had lost more to begin with, averaging 20.9% during the 36-week lead-in. Proportionally the pattern is similar: substantial regain in both. The more useful SURMOUNT-4 figure is that 89.5% of those continuing kept at least 80% of their loss, against 16.6% of those who stopped. Share this

Will my PMOS symptoms come back if I stop?
No trial has measured this, so the honest answer is that it is likely but unproven. No GLP-1 withdrawal trial has tracked androgens, menstrual cycles or PMOS symptoms after stopping. What is known is mechanism. The August 2026 tirzepatide trial in women with PMOS found benefits ran through a 34.13 cm2 reduction in visceral fat. Visceral fat drives insulin resistance, and insulin resistance drives ovarian androgen production. If visceral fat returns, that chain plausibly reassembles. The STEP 1 extension finding that cardiometabolic markers reverted toward baseline is consistent with that, though it did not measure reproductive hormones.

Can I take a lower maintenance dose instead of stopping?
This is the option with the most evidence behind it and it is worth raising with your prescriber. Both SURMOUNT-4 and STEP 4 compared continuing against stopping, and in both the continuing group kept improving rather than merely holding. Neither trial tested a reduced maintenance dose against a full dose, so the specific question of how low you can go has not been answered. What the trials do establish is that the difference between continuing and stopping is large, and much larger than most dose questions. Cost, access and side effect burden are all legitimate reasons to discuss dose reduction rather than cessation.

How do I keep the weight off after stopping?
No trial has tested a maintenance protocol after withdrawal, so this is reasoned rather than proven. The components with the strongest supporting logic are resistance training two to three times a week, protein at 1.2 to 1.6 g per kg of body weight, and a repeatable meal structure established before the taper rather than during it. The reasoning is that 28% of GLP-1 weight loss is lean mass, regain is preferentially fat, and muscle is the primary site of glucose disposal. Protecting muscle changes what you regain even if it does not prevent regain entirely. Tracking waist circumference alongside weight makes composition changes visible early.

Does stopping cause withdrawal symptoms?
Not in the sense of a drug withdrawal syndrome. GLP-1 receptor agonists are not habit-forming and stopping does not produce a physical withdrawal state. What returns is appetite, and it returns to roughly where it was before, which can feel dramatic after months of suppression. Gastrointestinal side effects resolve as the drug clears. The difficulty of stopping is behavioural and physiological rather than a withdrawal reaction, which matters because the two call for completely different responses.

Why did my doctor not warn me about this?
Sometimes the conversation genuinely does not happen, and sometimes it happens at the wrong moment. The withdrawal trials were published between 2021 and 2024, so the evidence is well established and not obscure. It is a reasonable thing to raise directly. Useful questions are what the plan is if you need to stop, whether a maintenance dose is possible, and what monitoring should continue afterwards. Going in with the trial names is fair game: STEP 1 extension, STEP 4 and SURMOUNT-4.

Is it worth taking a GLP-1 at all if the weight comes back?
That depends on what you want from it, and it is a fair question rather than a defeatist one. Weight loss while on treatment is real, and the metabolic and cycle improvements during that window are real. For PMOS specifically, the August 2026 trial found higher menstrual cycle recovery on tirzepatide plus metformin than on metformin alone. What the withdrawal evidence changes is the framing: this is ongoing management of a chronic condition, not a finite course. If you can plan for indefinite treatment or maintenance dosing, the calculation looks very different from planning for a six-month intervention.

What to do next

1. Work out your protein target today. Body weight in kg times 1.2 and times 1.6. That range is the number that decides what kind of tissue you keep.
2. Add one resistance session this week. Not three. One, repeated, beats three abandoned.
3. Measure your waist and write it down. Weight alone hides the composition change that matters most here.
4. Ask your prescriber about maintenance dosing before you ask about stopping. It is the option with actual trial evidence behind it.
5. Build the eating structure while the drug still makes it easy. Build your free PMOS meal plan now, so the habit exists before appetite returns.

How this article was made

Every figure comes from the published abstract of a named randomised trial, read in full before writing. The three withdrawal trials used are the STEP 1 trial extension (2022), STEP 4 (JAMA, 2021) and SURMOUNT-4 (JAMA, 2024). These are the only large randomised withdrawal studies of these drugs, which is why the same three appear in every credible discussion of this question.

Where evidence does not exist, this article says so rather than filling the gap. No withdrawal trial has measured PMOS symptoms, androgens or menstrual cycles after stopping, and no trial has tested a tapering schedule. Those gaps are marked in the text. The mechanistic reasoning about visceral fat is labelled as reasoning, not as a trial result.

Where to go from here

Stopping a GLP-1 with PMOS goes better when the plan exists before the taper does. The trials are consistent about what happens by default, which is exactly why the default is worth planning around.

• Build your free PMOS meal plan around your protein target while appetite is still suppressed.
• Protect the muscle first: protecting your muscle on a GLP-1 with PCOS.
• Compare your options in our honest guide to GLP-1s for PMOS.
• Get the day-to-day mechanics in what to eat on a GLP-1 with PCOS.
• Follow new research on our Telegram channel.

If you have come off a GLP-1, tell us what you wish you had set up beforehand. That is the part the trials do not record.